Glutamine Metabolism in Cancer
After glucose, glutamine is the nutrient many cancer cells consume most avidly. It serves as a carbon source that replenishes the TCA cycle and as a nitrogen donor for making nucleotides and other amino acids. Some tumours become so reliant on it that the dependence has been called glutamine addiction.
Quick Answer
After glucose, glutamine is the nutrient many cancer cells consume most avidly. It serves as a carbon source that replenishes the TCA cycle and as a nitrogen donor for making nucleotides and other amino acids. Some tumours become so reliant on it that the dependence has been called glutamine addiction.
Part of a topic cluster
Immuno-Oncology and Tumour Metabolism
Open the complete 15-article guideWhat Glutamine Provides
Glutaminase converts glutamine to glutamate, which is then converted to alpha-ketoglutarate, an intermediate that refills the TCA cycle (anaplerosis) when other intermediates are being drained for biosynthesis. This keeps the cycle turning to supply citrate for lipid synthesis and precursors for non-essential amino acids.
The nitrogen released also feeds nucleotide and hexosamine synthesis, and glutamine-derived carbon supports glutathione production, helping the cell manage oxidative stress.
What Drives the Dependence
MYC is a strong driver of glutamine uptake and glutaminase expression, so MYC-amplified tumours are often the most glutamine-dependent. The Warburg effect contributes indirectly: when glucose carbon is diverted away from full oxidation, glutamine takes over as the main anaplerotic source.
Not all tumours are glutamine-dependent, and dependence can shift with the microenvironment, so it is a context-specific vulnerability rather than a universal one.
Targeting It
Glutaminase inhibitors such as telaglenastat have been tested in renal cell carcinoma and other cancers. Activity as a single agent has been limited, partly because cells reroute metabolism when one pathway is blocked, and development has focused on combinations.
Broader glutamine-antagonist prodrugs are also in trials, including for their effects on the immune microenvironment. None is an established cancer therapy.
Interpretation and the Immune Angle
Glutamine dependence is not something a routine molecular report flags, and there is no companion test. MYC amplification is the nearest available proxy for a tumour likely to be glutamine-avid, and even then dependence is not guaranteed.
A newer reason for interest is immunometabolic: T cells also need glutamine, so a broad glutamine antagonist can cut both ways. Prodrugs engineered to concentrate in tumour tissue have shown, in models, that starving the tumour while relatively sparing T cells can improve anti-tumour immunity. Whether this translates is being tested.
Key Takeaways
- ·Glutamine refills the TCA cycle and donates nitrogen for nucleotide and amino-acid synthesis.
- ·MYC-driven tumours are often the most glutamine-dependent.
- ·Glutaminase inhibitors have shown limited single-agent activity and are being tested in combinations.
Put these genes in pathway context
Frequently asked questions
Which tumours are most glutamine-dependent?
MYC-driven tumours in particular, because MYC strongly increases glutamine uptake and glutaminase expression. Dependence is context-specific and can shift with the microenvironment, not universal.
What does glutamine actually provide a cancer cell?
Carbon to refill the TCA cycle when its intermediates are drained for biosynthesis, nitrogen for nucleotide and amino-acid synthesis, and support for glutathione production to manage oxidative stress.
Are glutaminase inhibitors approved?
No. Agents such as telaglenastat showed limited single-agent activity because cells reroute metabolism, and development has moved to combinations.
References
Continue Reading
The Warburg Effect: Why Cancer Cells Ferment Glucose
3 min read
The PI3K/AKT/mTOR Pathway in Cancer
4 min read
MTAP Deletion and PRMT5: A Metabolic Synthetic Lethality
3 min read
IDH1 and IDH2 Mutations: A Metabolic Change That Rewires the Epigenome
3 min read
BCL2 Family Proteins and Cancer Cell Survival
5 min read
Chromothripsis: One Catastrophe, Many Rearrangements
3 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
MYC has 40+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.